All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Mutation testing in AML:
What you need to know

with Charles Craddock, Ralph Hills, and Gail Roboz

Wednesday, April 23, 2025
17:30-18:30 BST

Register now

This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.

  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOG IN
You're logged in! Click here any time to manage your account or log out.
LOG IN
You're logged in! Click here any time to manage your account or log out.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2019-09-17T08:55:07.000Z

SOHO 2019 | What is the role of maintenance therapy for patients with AML?

Bookmark this article

During SOHO 2019, Houston, US, the AML Global Portal were pleased to speak to Prof Selina M. Luger from University of Pennsylvania, Philadelphia, US, about the role of maintenance therapy for patients with AML.

She highlights the importance of targeted therapies, such as anti-FLT3, picking suitable patients for such therapies, and hopes that we are getting closer to maintenance therapy with low toxicity and high efficacy.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

Thank you for rating this video.

The content addressed the learning objectives

Thank you for rating this video.

The content was relevant to my practice

Thank you for rating this video.

What is the role of maintenance therapy for patients with AML?

Your opinion matters

On average, how many patients with acute myeloid leukemia do you see in a month?
5 votes - 17 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox